Literature DB >> 17314336

DNA repair and survival in lung cancer--the two faces of Janus.

Adi F Gazdar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17314336     DOI： 10.1056/NEJMp068308

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  17 in total

1.  Genetic modifiers of carcinogen DNA adducts in target lung and peripheral blood mononuclear cells.

Authors:  Mi-Sun Lee; Li Su; Eugene J Mark; John C Wain; David C Christiani
Journal:  Carcinogenesis       Date:  2010-10-08       Impact factor: 4.944

2.  Association between eIF3α polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients.

Authors:  Xiaojing Xu; Lifang Han; Li Duan; Yingchun Zhao; Huaping Yang; Boting Zhou; Rui Ma; Ruixia Yuan; Honghao Zhou; Zhaoqian Liu
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

3.  Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients.

Authors:  Z Sun; J Chen; J Aakre; R S Marks; Y Y Garces; R Jiang; O Idowu; J M Cunningham; Y Liu; V S Pankratz; P Yang
Journal:  Ann Oncol       Date:  2010-05-03       Impact factor: 32.976

Review 4.  Parameters for individualizing systemic therapy in non-small cell lung cancer.

Authors:  Shirish M Gadgeel; Michele L Cote; Ann G Schwartz; Larry H Matherly; Antoinette Wozniak; Gerold Bepler
Journal:  Drug Resist Updat       Date:  2010-11-03       Impact factor: 18.500

Review 5.  Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.

Authors:  Shu-zhen Wei; Ping Zhan; Mei-qi Shi; Yi Shi; Qian Qian; Li-ke Yu; Yong Song
Journal:  Med Oncol       Date:  2010-02-09       Impact factor: 3.064

6.  Single nucleotide polymorphisms in nucleotide excision repair genes, cancer treatment, and head and neck cancer survival.

Authors:  Annah B Wyss; Mark C Weissler; Christy L Avery; Amy H Herring; Jeannette T Bensen; Jill S Barnholtz-Sloan; William K Funkhouser; Andrew F Olshan
Journal:  Cancer Causes Control       Date:  2014-02-02       Impact factor: 2.506

7.  How close are we to customizing chemotherapy in early non-small cell lung cancer?

Authors:  Georgios Ioannidis; Vassilis Georgoulias; John Souglakos
Journal:  Ther Adv Med Oncol       Date:  2011-07       Impact factor: 8.168

Review 8.  Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?

Authors:  Bartomeu Massuti; Jose Miguel Sanchez; Florentino Hernando-Trancho; Niki Karachaliou; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2013-06

9.  Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.

Authors:  Jeffrey G Schneider; Nosha Farhadfar; Abirami Sivapiragasam; Matthew Geller; Shahidul Islam; Elena Selbs
Journal:  Oncologist       Date:  2014-04-04

10.  ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy.

Authors:  Shigeru Sakano; Satoshi Ogawa; Yoshiaki Yamamoto; Jun Nishijima; Yoshihiro Miyachika; Hiroaki Matsumoto; Takahiko Hara; Hideyasu Matsuyama
Journal:  Mol Clin Oncol       Date:  2013-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.